CDRD works with world-class organizations to develop funding partnerships aimed at advancing and commercializing selected promising discoveries. To date, CDRD has established four such Innovation Funds to support projects. The structure of these partnerships provides not only financial resources for selected projects, but also gives CDRD and PIs access to world-class industry expertise to help develop project plans.
Pfizer-CDRD Innovation Fund
Pfizer Canada has provided several million to CDRD to establish a fund aimed at accelerating the commercialization of some of Canada’s most promising academic research projects into high-value medicines that form the basis for new companies or licensing opportunities. This fund leverages additional support from the NCE Centres of Excellence in Commercialization and Research Program, and is administered by CDRD based on the recommendations of an expert review panel.
GSK-CDRD Innovation Fund
This strategic collaboration provides new project-based financial resources as well as leading drug development expertise to support the development and commercialization of health research conducted in Canadian research institutions. The GSK-CDRD Innovation Fund supports certain early-stage projects conducted by CDRD, and carried out in collaboration with academic investigators at CDRD’s affiliated institutions and/or hospital-based research centers. A joint Innovation Committee comprised of both GSK and CDRD representatives as well as external reviewers reviews and select the projects to be supported from this fund.
Western Canada Innovation Fund
A partnership with Johnson & Johnson (COSAT) which also includes investments from the Provinces of British Columbia and Alberta. The Western Canada Innovation Fund is co-managed by a joint steering committee that oversees this seed fund to enable early-stage innovative discoveries within the health sciences so that they may advance along a pathway to commercialization. Representatives from Alberta, British Columbia/CDRD and COSAT jointly assess opportunities for the collaboration, funding, management, and commercialization of these health research projects from British Columbia and Alberta.
Genome BC-CDRD Development Fund
The Genome BC–CDRD Development Fund was created to accelerate the development of commercially promising projects related to advances and discoveries stemming from genome sciences and genetics. Genome BC has earmarked $1 million toward the fund on a project-by-project basis. CDRD will contribute up to $1 million in expertise, facilities, and equipment time.
In addition, CDRD’s commercial arm, CDRD Ventures Inc. has also established commercial partnerships with GlaxoSmithKline (GSK) and F. Hoffman-La Roche Inc. (Roche) whereby both companies have established committed funds to support and jointly develop selected technologies under the management of CVI. For more information on these partnerships, visit CVI Inc. by clicking here.